Bristol-Myers Squibb Gets FDA Approval for Hodgkin’s Lymphoma Treatment

Bristol-Myers Squibb Company (NYSE:BMY) is included among the 15 Large Cap Stocks with Highest Dividends.

Bristol-Myers Squibb Company (NYSE:BMY) discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.

Bristol-Myers Squibb Company (NYSE:BMY) announced on March 20 that the U.S. Food and Drug Administration had approved the company’s combination treatment for adults and adolescents aged 12 and older ‌with previously untreated stage III or IV classical Hodgkin’s lymphoma. The antitumor therapy, called Opdivo, had previously received the green light to treat various advanced or metastatic cancers, including ​melanoma, non-small cell lung cancer, and kidney cancer.

The regulatory authority’s decision is based on a late-stage study of 994 patients, which demonstrated that the ‌treatment significantly improved progression-free survival compared with brentuximab vedotin.

Hodgkin’s lymphoma, also known as Hodgkin’s disease, is the most common form of cancer in patients aged 15 to 19. It starts in white blood cells, which are part of the body’s immune system, a cancer that starts in white blood cells.

Monica Shaw, MD, Senior Vice President of Oncology Commercialization at Bristol-Myers Squibb Company (NYSE:BMY), stated:

“These approvals represent a defining moment for people living with classical Hodgkin Lymphoma. In the U.S., we are particularly proud that Opdivo in combination with AVD now stands as an immunotherapy combination available for adults and pediatric patients, ages 12 and older, with previously untreated advanced disease. Concurrently, in the EU, Opdivo in combination with brentuximab vedotin has also achieved a milestone as the first immunotherapy combination for certain relapsed or refractory patients. These milestones reflect our continued commitment to advancing science that meaningfully improves the lives of patients and families worldwide.”

READ NEXT: 13 Oil Stocks with Highest Dividends and 14 Best Energy Stocks to Buy According to Wall Street Analysts

Disclosure: None. Follow Insider Monkey on Google News.